Endo Int'l (ENDP) Tops Q4 EPS by 4c; Guides FY15 EPS, Revs Below Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Endo Pharmaceuticals (ENDP) Target Lifted to $100 at Guggenheim
March 2, 2015 3:19 PM ESTGuggenheim analyst Swati Kumar reiterated a Buy rating and boosted its price target on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) to $100.00 (from $80.00) after the the company announced Q4 results and the sale of its men's health and prostate health business for $1.65B to Boston... More
Boston Scientific (BSX) to Acquire Endo's AMS Urology Portfolio in $1.65B Deal
March 2, 2015 7:02 AM ESTEndo Int'l (NASDAQ: ENDP) announced it has entered into a definitive agreement with Boston Scientific (NYSE: BSX), under which Boston Scientific will acquire Endo's American Medical Systems' (AMS) Men's and Prostate Health businesses for up to $1.65 billion, with $1.6 billion in cash payable at closing. Endo is also eligible to receive a potential milestone payment of $50 million in cash conditioned on Boston Scientific achieving certain product revenue... More
